Pediatrics · LP-018
Metronidazole Oral suspension
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-018Pediatrics
- Generic identity
- MetronidazoleOral suspension
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-018
- Generic identity
- Metronidazole
- Presentation
- Oral suspension
- Catalogue strength
- 200 mg/5 mL
- Catalogue pack
- Bottle 60 mL / 100 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: metronidazole.
- Dosage form: oral suspension.
- Catalogue concentration: 200 mg/5 mL.
- Catalogue bottle options: 60 mL and 100 mL.
- Catalogue category: Pediatrics; category is navigation only.
Layer 02 · Unresolved product-specific fields
- Approved indication, age/weight eligibility and dose instructions for this exact product.
- Suspension vehicle, excipients, whether shaking is required and measuring-device specification.
- Pack/SKU status for 60 mL versus 100 mL and any after-opening limits.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 200 mg/5 mL | Oral suspension | — | Bottle 60 mL | Paediatric eligibility, formula and bottle-specific approval are not established. |
| B | 200 mg/5 mL | Oral suspension | — | Bottle 100 mL | Paediatric eligibility, formula and bottle-specific approval are not established. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Metronidazole is an antimicrobial used against selected anaerobic bacteria and certain protozoal infections. The indication and route are specific: an oral product is not equivalent to a skin or vaginal preparation. Its role should be established through diagnosis and current treatment guidance. This ingredient-level education does not provide a regimen or establish any approved Luang Pharma claim for the proposed tablet or oral suspension.
Clinical context and therapeutic role
Clinical contexts include selected dental, abdominal, genital and parasitic infections, but treatment depends on the organism, disease severity and local recommendations. Some conditions require combination therapy or a non-drug intervention; an ingredient catalogue cannot determine that plan. The clinician reviews liver function, neurologic history, pregnancy considerations and interacting medicines. Persistent or recurrent symptoms need reassessment because they may reflect a different diagnosis, reinfection or antimicrobial resistance.
Selected safety context
Nausea and a metallic taste are common. Numbness, tingling, balance problems, seizures or other neurologic changes need prompt medical review. Severe skin reactions and liver injury are uncommon but important. Alcohol and some alcohol-containing preparations may cause an unpleasant reaction; follow the exact label and pharmacist’s advice. Interactions with warfarin, lithium and other medicines require review. Severe diarrhoea, jaundice or signs of allergy should not be ignored.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue identifies an oral suspension. A measured volume is meaningful only with the verified concentration and correct mixing instructions. The suspension vehicle, excipients and product-specific behavior cannot be inferred from the ingredient name, and different concentrations must not be compared using volume alone.
Follow the approved instructions for shaking and use a suitable calibrated oral device. Keep the bottle properly closed and labeled. Storage conditions and the permitted period after opening must be established from the actual supplied product; this profile does not assign either.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product formula/specification for the oral suspension.
Approved label/leaflet with age/indication, shaking/measuring and administration instructions.
Container/closure and measuring-device specification for each proposed bottle.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: MetronidazoleArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Metronidazole tablets — official US label exampleArchived source classification: US official drug label example | Source revision recorded: Label updated 1 July 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-018.
Professional enquiries
Request product-specific evidence for LP-018.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.